# OnCo record nct04919226 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04919226/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04919226", "NCT04919226" ;
  schema:name "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE"@en ;
  schema:alternateName "COMPOSE"@en ;
  schema:description "A phase 3 trial of 177Lu-edotreotide, Temozolomide, Capecitabine, Everolimus, Leucovorin (folinic acid) and Oxaliplatin in neuroendocrine tumours, run by ITM Solucin GmbH, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04919226/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04919226> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-12-21" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/grade-3-net/>, <https://onco.cc/cancers/pancreatic-net/>, <https://onco.cc/cancers/small-intestinal-net/> ;
  onco:technologies <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:drugs <https://onco.cc/drugs/itm-11/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/leucovorin/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/capecitabine-temozolomide/> ;
  onco:companies <https://onco.cc/companies/itm/> .